Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.
AUTOR(ES)
Ignarro, L. J.
RESUMO
Nitric oxide is the active chemical species responsible for the vasodilator action of nitroglycerin, nitroprusside, and related nitrovasodilators. The most potent vasodilator and inhibitor of platelet aggregation known, nitric oxide was recently discovered to occur endogenously as the endothelium-derived relaxing factor. The pharmacology of endothelium-derived nitric oxide is virtually identical to that of the clinically used nitrovasodilators. Although endothelium-derived relaxing factor or endothelium-derived nitric oxide seems to be important in animals, its significance in humans still needs to be shown. We review the recent discoveries in the identification, biosynthesis, metabolism, and biologic actions of endothelium-derived nitric oxide, its significance in humans, and its relation to the clinically used nitrovasodilators.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1002676Documentos Relacionados
- Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.
- Role of endothelium-derived nitric oxide in the regulation of blood pressure.
- Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.
- Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling.
- Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
